Gilead Sciences, Inc. Market Cap

Data as of June 01, 2026

How It's Calculated

What This Means

Gilead Sciences, Inc. has a market capitalization of $166.90B, classifying it as Large Cap — a major company by market standards. Market cap represents the total value of all outstanding shares and is a key indicator of a company's size.

About Gilead Sciences, Inc.

Gilead Sciences, Inc. (GILD) operates in the Healthcare sector, specifically in Drug Manufacturers - General. With a market capitalization of about $166.90B, it ranks as a large-cap stock — a major established company.

Shares recently traded near $134.43, within a 52-week range of $104.46 to $157.29 (-14.5% from the high, +28.7% from the low). Beta of 0.33 indicates relatively lower volatility versus the market.

Trailing profit margin is about 31.0%, signaling a strong profit margin relative to many peers.

Understanding This Metric

Market capitalization sums the market value of all outstanding shares. It helps classify Gilead Sciences, Inc. by size — mega-cap, large-cap, and mid-cap stocks tend to have different liquidity, volatility, and index inclusion profiles. Size alone does not determine quality, but it frames risk and how widely the stock is held.

Sector Comparison

Among Healthcare names on our S&P 100 coverage, Gilead Sciences, Inc.'s market cap of $166.90B can be compared with peers such as LLY ($985.37B), JNJ ($542.42B), UNH ($345.38B). Sector context helps interpretation, but each company's growth profile and balance sheet differ — use multiple metrics before drawing conclusions. View all Healthcare stocks.

Key Takeaways

• GILD is grouped in the Healthcare sector for peer comparisons.
• Recent beta of 0.33 suggests lower-than-market price sensitivity.
• Trailing profit margin of 31.0% provides context for how much earnings support the headline multiple.

Related Tools & Guides

Explore calculators and guides connected to this metric, or view all metrics for GILD.

Other GILD Metrics

Frequently Asked Questions